Basic Information
| LncRNA/CircRNA Name | HIF1A-AS2 |
| Synonyms | HIF1A-AS2, 3'aHIF-1A, aHIF |
| Region | GRCh38_14:61715558-61751097 |
| Ensemble | ENSG00000258667 |
| Refseq | NR_045406 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR etc. |
| Sample | bladder cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | In our study, we first reported that HIF1AAS2 was up-regulated in bladder cancer tissues and cells, and HIF1A-AS2 expression level in bladder cancer tissues is positively associated with advanced clinical pathologic grade and TNM phase. Cell proliferation inhibition, cell migration suppression and apoptosis induction were observed by silencing HIF1AAS2 in bladder cancer T24 and 5637 cells. Overexpression of HIF1A-AS2 in normal SV-HUC-1 cells could promote cell proliferation, cell migration and anti-apoptosis. In conclusion, our data suggested that HIF1A-AS2 plays oncogenic role and can be used as a therapeutic target for treating human bladder cancer. |
| Pubmed ID | 27018306 |
| Year | 2016 |
| Title | Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer |
External Links
| Links for HIF1A-AS2 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |